BiotechTube
Home/Nuvalent/Christopher Turner, MD
CT

Christopher Turner, MD

Chief Medical Officer

Nuvalent

Therapeutic Areas

OncologyPrecision Medicine

Nuvalent Pipeline

DrugIndicationPhase
Zidesamtinib (NVL-520)TKI pre-treated advanced ROS1+ NSCLCPhase 2
Neladalkib (NVL-655)TKI pre-treated advanced ALK+ NSCLCPhase 2
NVL-330Advanced HER2-altered NSCLCPhase 1

Leadership Team at Nuvalent

JP
James Porter, PhD
Chief Executive Officer
AB
Alex Balcom, MBA, CPA
Chief Financial Officer
HP
Henry Pelish, PhD
Chief Scientific Officer
View full Nuvalent profile